• 0 Posts
  • 10 Comments
Joined 6 months ago
cake
Cake day: December 29th, 2023

help-circle




  • totally agree on almost everything you said, but whilst we’re kinda “expecting it to be paid back”, we realised some time between the end of WW1 and the end of WW2 that expecting to be paid back for stuff like this tends to leave a country very very bitter and generally unable to pay back the money anyway (from what i understand)

    i think whilst it’ll be “on the books”, in the long run it’ll be a case of “you owe us one; make sure you vote to align with the west”

    and TBH, that’s good for everyone (not that the west is perfect, but it’s - in general - a heck of a lot better than the other alternatives)






  • they’re talking about an API though, which changes the game a bit. i agree regarding the UX of the situation, but i don’t think the API is the right place to do something like that

    the API should follow the theory of least surprise, and always work the same rather than follow some unwritten rule in certain situations. i say this for 2 reasons (that i can think of right now):

    • unwritten rules like not following expiry lead to “worked on my machine” and difficult to debug scenarios
    • if you break standards like JWT, you can’t do things like offload auth validation to some kind of ingress router because you have extra rules that don’t follow the spec

    you can implement the same functionality in the client app pretty easily which, IMO, is where UX lives. perhaps putting an expiry with “prices refresh in 5min” to get around the complexity of the fact that prices may or may not change or stay the same… i don’t think anyone enjoys when their ride share surge price changes after the app “times out” searching for driver (as in something out of their control, like an opaque timeout) but if they know the amount of time they have they feel in control


  • i think the key here is:

    zosurabalpin doesn’t seem to work on any other Gram-negative bacteria besides A. baumannii. The proteins in the LPS transporter complex are not conserved across different bacteria. Thus, targeting the LPS transporters of other nefarious Gram-negative bacteria will take yet more drug development research. One bright side of this, as Gugger and Hergenrother note in their commentary, is that it may produce species-specific antibiotics, which could protect patients’ microbiomes from being obliterated by broad-spectrum drugs, which we now appreciate is bad for human health.

    And, of course, with any new antibiotic, there’s the inevitability that bacteria will develop resistance. The researchers already found that select mutations in the LPS transporter machinery can knock back the drug’s potency. Also, A. baumannii doesn’t need LPS to stay alive. That said, simply blocking LPS production would leave A. baumannii more vulnerable, and it’s unclear how that trade-off will play out in clinical settings.